- 935U83
- A-74704, A-77003 & A-80987
- AL-721
- ALX40-4C
- AMD3100
- Aplaviroc
- Ampligen
- Atevirdine
- Aztec
- BB-10010
- Butyl DNJ
- Capravirine
- Castanospermine
- Compound Q
- DAPD
- DFC (dexelvucitabine)
- DMP-450
- dOTC
- DPC 083
- DPC 681 and DPC 684
- DPC 961 and DPC 963
- Emivirine
- FLT
- GEM 92
- GW420867X
- KNI-272
- L-697,661
- Lithium gamma-linolenate
- Lodenosine
- Loviride
- Oxpentifylline
- Quinotaline
- RO033-4649
- Ro 24-7429
- SC-52151 & SC-55389A
- SID791
- SPC3
SID791
SID791 is an experimental drug that belongs to a new class of compounds known as bicyclams. In the test-tube, it appears to prevent HIV from infecting human cells, either by preventing the virus gp120 molecule from fusing with the cells CD4 molecule, or by preventing the release of the virus genetic material into the cell after it has fused.
SID791 is also known as JM3100, and was being developed by Sandoz. No further data on this compund has been reported since 1996.
References
Bridger GJ et al. Synthesis and structure-activity relationships of phenylenebis-(methylene)-linked bis-tetraazamacrocycles that inhibit HIV replication. Effects of macrocyclic ring size and substituents on the aromatic linker. J Med Chem 38:366-378, 1995. De Vreese K. et al. The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication. J Virology 70:689-696, 1996. DeClercq E et al. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrobial Agents and Chemotherapy 38:668-674, 1994.
latest aidsmap news
- Fluconazole shown to be more effective against cryptococcal meningitis at higher dose
- Promising early results for large-scale study of community-level HIV prevention initiative
- GNP+ launches website documenting global HIV exposure / transmission laws and prosecutions
- Widespread resistance to antiretrovirals among children in the Central African Republic
- Children starting HIV treatment in sub-Saharan Africa have a low risk of death
- Different paediatric responses to antiretroviral therapy in Uganda and the United Kingdom/Ireland may reflect differences in nutrition and access to cotrimoxazole
- Rare abacavir liver side-effects reported
- Abacavir treatment doesn't cause changes in biomarkers linked to heart attack, suggests small study
- Traditional healers could play key role in ART rollout
- HIV testing for mothers and children must expand, UN report shows
